Bioiberica, a provider of identification, extraction and development of animal-derived active pharmaceutical ingredients (APIs), has launched its natural thyroid API for the treatment of hypothyroidism. Replacing or supplementing the hormones that are ineffectively produced by the human thyroid gland, the API specifically targets patients who prefer a natural origin treatment or those who continue to experience symptoms despite using the standard synthetic therapy.
 
“There is a clear subset of patients suffering from hypothyroidism with persistent symptoms despite following a standard synthetic thyroid treatment,” said Javier Velasco-Alvarez, R&D director, Bioiberica. “Our natural thyroid API, extracted from porcine thyroid glands, targets this unmet need. It contains the hormones – tetraiodothyronine, also known as thyroxine or T4, and triiodothyronine, otherwise known as liothyronine or T3 – that are naturally produced by the thyroid gland. Scientific evidence shows that thyroid API is an effective treatment from a natural origin.”   
 
According to Bioiberica, the new API is manufactured to European pharmaceutical standards, and offers quality, safety and regulatory compliance due to the company’s vertically-integrated supply chain, through which it can offer full traceability, security and sustainability.
 
Jaume Reguant, healthcare director, Bioiberica, said, “The development of our new thyroid API is the direct result of collaborative partnership with a key player in the pharmaceutical market. By combining our partner’s knowledge with our leading expertise in the identification and manufacture of specific biomolecules, we have successfully developed a solution that looks to address one of today’s many healthcare challenges.”